Tramadol plus Acetaminophen

ApprovedSmall molecule

Johnson & Johnson

Tramadol plus Acetaminophen is one of 157 small molecule programs targeting Low back pain. It is currently in Approved.

Indications

Total Trials

Active Trials

156

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainActive, not recruiting

Chronic PainActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

OsteoarthritisActive, not recruiting

Diabetic NeuropathyActive, not recruiting

Low Back PainApproved

Active, not recruiting

Chronic PainPhase 3

Active, not recruiting

Rheumatoid ArthritisApproved

Active, not recruiting

OsteoarthritisApproved

Active, not recruiting

Diabetic NeuropathyApproved

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Tramadol plus Acetaminophen

Johnson & Johnson

Approved

1 2

Cimzia

UCB

Preclinical

30 3

Remicade

OOrganon and Co

Preclinical

43 4

Arcoxia

Novartis

Preclinical

4 5

Ilaris

Novartis

Preclinical

3 6

Actos

Takeda

Preclinical

2 7

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 8

Cataflam

Rituxan

7 10

Certolizumab

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoarthritis3 trials

A Study of the Tolerability of Titrated Dose Tramadol/Acetaminophen Combination Tablet in Korean Patients With Osteoarthritis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01063842·250 enrolled

A Comparative Study of Tramadol Hydrochloride Plus Acetaminophen Tablets Maintenance Versus Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Maintenance in Participants With Knee Osteoarthritis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00635349·143 enrolled

An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00752661·119 enrolled

Chronic pain2 trials

An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00736853·321 enrolled

A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00736957·219 enrolled

Pain1 trial

A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00737048·328 enrolled

Rheumatoid Arthritis1 trial

ULTRACET (Tramadol Hydrochloride and Acetaminophen) for the Treatment of Rheumatoid Arthritis Pain.

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00246168·277 enrolled

ESS1 trial

A Study to Assess the Bioequivalence of a New ULTRACET Extended Release (ER) Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01778075·56 enrolled

5 more indications

Moderate to Severe Postoperative Pain1 trial

A Study Comparing the Effectiveness and Safety of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen With Immediate Release (IR) Tramadol HCl/Acetaminophen in Participants With Moderate to Severe Postoperative Pain

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01814878·320 enrolled

Acetaminophen1 trial

A Comparison of the Effectiveness and Safety of ULTRACET® (Tramadol Hydrochloride/Acetaminophen) Versus ULTRAM® (Tramadol Hydrochloride) Versus Placebo in Patients With Pain After Oral Surgery

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT00236483·456 enrolled

Diabetic Neuropathy1 trial

A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00634543·162 enrolled

Breakthrough Pain1 trial

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Completed·JJohnson & Johnson Taiwan Ltd·Phase 4·NCT00576173·60 enrolled

Low back pain1 trial

A Study of the Effectiveness and Safety of Tramadol HCl/Acetaminophen Compared to Placebo in Treating Acute Low Back Pain

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT00210561·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Tramadol plus Acetaminophen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tramadol plus Acetaminophen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tramadol plus Acetaminophen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Johnson & Johnson

Tramadol plus Acetaminophen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoarthritis3 trials

Chronic pain2 trials

Pain1 trial

Rheumatoid Arthritis1 trial

ESS1 trial

Moderate to Severe Postoperative Pain1 trial

Acetaminophen1 trial

Diabetic Neuropathy1 trial

Breakthrough Pain1 trial

Low back pain1 trial

References

Drug Info

Quick Facts

Related News